- Nu-Med reported sales of over 60 million euros in 2023
- The transaction enables EI’s Polish Enterprise Fund VII to exit
- EI is a private equity firm in Central and Eastern Europe
Enterprise Investors (El) will sell Nu-Med, a Polish provider of radiotherapy treatments for cancer patients, to Afildea.
Nu-Med is based in Elbląg and reported sales of over 60 million euros in 2023.
The partnership between Nu-Med and EI began in 2013, when the company acquired a significant minority stake in the company, which at the time operated a single radiotherapy centre in Elbląg. The year before, EI made its first investment in radiotherapy in Katowice. The two radiotherapy centres subsequently merged under the name Nu-Med and two more treatment centres were opened: one in Tomaszów Mazowiecki and the other in Zamość.
The transaction provides an exit for EI’s Polish Enterprise Fund VII.
“We are very proud that we have provided intensive care to almost 70,000 patients during our investment period,” said Michał Rusiecki, managing partner of EI, in a statement. “From a single radiotherapy center, we have transformed Nu-Med into a leading provider of cancer treatments.”
The deal must be approved by the Polish Office of Competition and Consumer Protection.
EI is a private equity firm in Central and Eastern Europe.
Afildea is a pan-European healthcare provider offering cancer treatment, advanced imaging diagnostics and community-based outpatient clinics, among others. The company is majority owned by Groupe Bruxelles Lambert (GBL), a Belgian investment holding company.
